Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Leritrelvir was adopted
in 1 country.
Submit updates/corrections .
Summary.
Nov 23 |
Leritrelvir for COVID-19: real-time meta analysis of 2 studies | |
| Statistically significant lower risk is seen for recovery and viral clearance. 2 studies from 2 independent teams (both from the same country) show significant improvements. Meta analysis using the most serious outcome reported shows.. | ||
Jul 6 |
et al., Quantitative Biology, doi:10.1002/qub2.60 | Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses |
| In Vitro study showing that leritrelvir and GC376 remained effective against some nirmatrelvir- and ensitrelvir-resistant Mpro mutants. Leritrelvir showed better broad-spectrum activity against other pathogenic coronaviruses compared to e.. | ||
Mar 29 |
et al., Nature Microbiology, doi:10.1038/s41564-024-01618-9 | Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir |
| In Vitro and K18-hACE2 transgenic mouse study showing the preclinical efficacy of RAY1216, an inhibitor of the SARS-CoV-2 main protease (Mpro), against multiple SARS-CoV-2 variants. RAY1216 forms a covalent bond with the catalytic cystein.. | ||
Jan 31 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102359 | Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial |
| 17% improved recovery (p=0.002) and 16% improved viral clearance (p=0.01). RCT 1,359 COVID-19 outpatients showing faster recovery with leritrelvir monotherapy (without ritonavir), 251 vs. 271 hours, and improved viral clearance. There were no significant differences in adverse events between groups. | ||
Sep 30 2023 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102189 | Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial |
| 35% faster recovery (p=0.04) and 21% improved viral clearance (p=0.01). RCT 60 hospitalized COVID-19 patients in China showing imporoved recovery and viral clearance with RAY1216, a 3CLpro inhibitor. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.